Skip to content
OpenCapital
Get started

BioMarin Pharmaceuticals BMRN United States — Revenue

Discontinued — last reported Q3 '21

Similar metrics at other companies

Summit Therapeutics logo
SMMTUnited States — Revenue
$0—
Moderna logo
MRNAUnited States — Total Revenue
$299.75M-32.8%
Incyte logo
INCYUnited States — Total revenues
$1.17B+19.3%
Guardant Health logo
GHUnited States — Revenue
$284.63M+47.0%
Penumbra logo
PENUnited States — Revenue
$296.39M+15.4%
Sanmina Corp logo
SANMUS — Revenue
$400.89M+24.8%

Other financials

Income statement

See full
Revenue$766.2M+2.8%
Gross profit$571.2M-3.8%
Operating income$129.6M-42.1%
Net income$105.5M-43.2%
EPS (diluted)$0.54-43.2%

Balance sheet

See full
Cash & equivalents$3.1B+193%
Total debt$1.4B+138%
Total equity$6.2B+7.2%
Total assets$8.6B+20.2%

Cash flow

See full
Operating cash flow$220.7M+26.5%
CapEx$20.9M+24.8%
Free cash flow$199.7M+26.7%

Valuation

See full
Market cap$10.57B-19.4%
Enterprise value$8.93B-29.3%
P/E21.1×-22.7×
P/S3.3×-1.2×

Profitability

See full
Gross margin76.5%-2.9pp
Operating margin19.9%+7.2pp
Net margin16.8%+5.1pp
FCF margin23.7%+2.5pp

Returns & leverage

See full
Return on equity9.1%+2.8pp
Debt / equity0.2×+0.1×
Current ratio5.8×+0.3×

Where this comes from

Reported directly by BioMarin Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: BioMarin Pharmaceuticals’s 10-Q, filed October 29, 2021, on SEC EDGAR. View the filing →

Ask your AI about BioMarin Pharmaceuticals's united states — revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioMarin Pharmaceuticals's united states — revenue?
BioMarin Pharmaceuticals (BMRN) reported united states — revenue of $196.24M in Q3 2021.
What does united states — revenue mean?
The total amount of money generated from sales specifically within the United States market.
How do you interpret united states — revenue?
An increase indicates successful commercial execution, market share expansion, or effective pricing strategies in the U.S., whereas a decrease may signal competitive pressure, regulatory headwinds, or loss of market exclusivity.
How does united states — revenue compare across companies?
Most global pharmaceutical companies provide geographic revenue breakdowns, making this a standard benchmark for evaluating regional performance and market-specific growth trajectories.